Pfizer and new partner BioNTech nab approval to start closely watched COVID-19 vax trial

Pfizer has been granted approval in partner BioNTech’s native country Germany to kick-start a phase 2 test of their experimental mRNA vaccine for COVID-19.

Pfizer and BioNTech penned their COVID-19 partnership back in March, with the biotech getting $185 million in upfront payments and $563 million on the table in the form of biobucks.